How Does Moderna’s New Melanoma Vaccine Work – and Could It Treat Other Cancers?
6 Articles
6 Articles
The medical world is talking about a groundbreaking new development in the fight against cancer. A personalized mRNA vaccine developed for melanoma, the deadliest type of skin cancer, significantly reduced the risk of cancer recurrence in phase three clinical trials. Experts describe this achievement as the beginning of a completely "personalized" treatment era in medicine.
Big pharma companies Moderna and Merck push new mRNA cancer vaccine to prevent melanoma recurrence
According to two U.S.-based pharmaceutical companies, a phase 3 clinical trial has allegedly shown that a personalized mRNA cancer vaccine improves outcomes when added to standard immunotherapy in patients with high-risk melanoma.
Promising results for a personalized cancer vaccine: treatment with messenger RNA given to patients with high risk melanoma is designed individually and is given in multiple doses at certain intervals.
Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more
Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized cancer vaccine. Check out our team’s detailed analysis on the results, the unknowns and Moderna’s massive ...
The cancer drug Keytruda from Merck & Co. is the most powerful drug in the world. The combination with the skin cancer vaccine from Moderna gives the drug even new momentum.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
